In recent developments, Pfizer and BioNTech have won their case against CureVac's UK COVID vaccine patent. While the FDA had previously announced a partial hold over the phase III trial of BioNTech's NSCLC therapy. Moreover, BioNTech and DeepMind are working together to bring AI-assistance to scientific labs. BioNTech is expected to report its Q3 earnings soon, and observers are keen to see whether it can beat predictions. Meanwhile, BioNTech and CEPI have joined forces to boost Africa’s mRNA vaccine landscape. A notable setback for BioNTech is a loss of €808M due to the challenges dealing with the seasonal COVID vaccine market. However, their mRNA Cancer Vaccine Combo with Regeneron's has moved into Phase II after clearing melanoma trials. FDA has lifted the partial hold on BioNTech's cancer drug trial. Furthermore, Moderna has seen a patent win against the Pfizer-BioNTech COVID shot in Europe. Finally, BioNTech's mRNA vaccine manufacturing capacity in Africa is set to be boosted by $145M.
BIONTECH News Analytics from Mon, 20 Nov 2023 19:17:53 GMT to Fri, 25 Oct 2024 15:31:01 GMT - Rating 0
